Nurix Therapeutics Inc (NASDAQ:NRIX) shares, rose in value on Friday, January 24, with the stock price down by -0.15% to the previous day’s close as strong demand from buyers drove the stock to $19.93.
Actively observing the price movement in the last trading, the stock closed the session at $19.96, falling within a range of $19.7275 and $20.39. The value of beta (5-year monthly) was 2.2. Referring to stock’s 52-week performance, its high was $29.56, and the low was $7.65. On the whole, NRIX has fluctuated by 0.50% over the past month.
With the market capitalization of Nurix Therapeutics Inc currently standing at about $1.41 billion, investors are eagerly awaiting this quarter’s results, scheduled for in February.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 12.88M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NRIX’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of NRIX currently trading nearly 3.07% and -5.00% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 50.22, while the 7-day volatility ratio is showing 4.41% which for the 30-day chart, stands at 5.34%. Furthermore, Nurix Therapeutics Inc (NRIX)’s beta value is 2.14, and its average true range (ATR) is 1.13.
A comparison of Nurix Therapeutics Inc (NRIX) with its peers suggests the former has fared considerably weaker in the market. NRIX showed an intraday change of -0.15% in last session, and over the past year, it grew by 148.81%%.
Data on historical trading for Nurix Therapeutics Inc (NASDAQ:NRIX) indicates that the trading volumes over the past 10 days have averaged 0.75 and over the past 3 months, they’ve averaged 899.34K. According to company’s latest data on outstanding shares, there are 70.84 million shares outstanding.
Nearly 2.74% of Nurix Therapeutics Inc’s shares belong to company insiders and institutional investors own 95.12% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 10.79 million shares as on 2024-12-31, resulting in a short ratio of 11.73. According to the data, the short interest in Nurix Therapeutics Inc (NRIX) stood at 1635.00 of shares outstanding as of 2024-12-31; the number of short shares registered in 2024-11-29 reached 9.35 million. The stock has risen by 5.79% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NRIX stock heading into the next quarter.
